For research use only. Not for therapeutic Use.
Prinomastat（Cat No.:M034885）is a selective matrix metalloproteinase (MMP) inhibitor designed to target enzymes like MMP-2, MMP-3, MMP-9, and MMP-14, which play key roles in tumor growth and metastasis. By inhibiting MMPs, Prinomastat disrupts the degradation of extracellular matrix components, slowing tumor invasion and angiogenesis. It has been investigated as a potential adjunct therapy in cancer treatment, particularly for solid tumors. Its specificity for MMPs involved in cancer progression has made Prinomastat valuable in oncology research, aimed at understanding and halting cancer metastasis and related pathologies.
| Catalog Number | M034885 |
| CAS Number | 192329-42-3 |
| Molecular Formula | C18H21N3O5S2 |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide |
| InChI | InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1 |
| InChIKey | YKPYIPVDTNNYCN-INIZCTEOSA-N |
| SMILES | CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C |
| Reference | </br>1:Crystal structure of human cytochrome P450 2D6 with prinomastat bound. Wang A, Savas U, Hsu MH, Stout CD, Johnson EF.J Biol Chem. 2012 Mar 30;287(14):10834-43. doi: 10.1074/jbc.M111.307918. Epub 2012 Feb 3. PMID: 22308038 Free PMC Article</br>2:Inhibiting matrix metalloproteinases with prinomastat produces abnormalities in fetal growth and development in rats. Younis HS, Jessen BA, Wu EY, Stevens GJ.Birth Defects Res B Dev Reprod Toxicol. 2006 Apr;77(2):95-103. PMID: 16607633 </br>3:Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA.Invest New Drugs. 2006 Mar;24(2):135-40. PMID: 16502351 </br>4:Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. Bissett D, O/’Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA.J Clin Oncol. 2005 Feb 1;23(4):842-9. PMID: 15681529 </br>5:The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinase, on a new animal model of epiretinal membrane. El-Bradey MH, Cheng L, Bartsch DU, Niessman M, El-Musharaf A, Freeman WR.Retina. 2004 Oct;24(5):783-9. PMID: 15492635 </br>6:Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat. Wiart M, Fournier LS, Novikov VY, Shames DM, Roberts TP, Fu Y, Shalinsky DR, Brasch RC.Technol Cancer Res Treat. 2004 Aug;3(4):377-82. PMID: 15270589 </br>7:The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ.Cancer Res. 2004 Apr 1;64(7):2328-32. PMID: 15059880 Free Article</br>8:Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G.Clin Cancer Res. 2004 Feb 1;10(3):909-15. PMID: 14871966 Free Article</br>9:Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Liu J, Tsao MS, Pagura M, Shalinsky DR, Khoka R, Fata J, Johnston MR.Lung Cancer. 2003 Dec;42(3):335-44. PMID: 14644522 </br>10:Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Behrendt CE, Ruiz RB.Thromb Haemost. 2003 Oct;90(4):734-7. PMID: 14515196 |
